Developers testing new therapies for lupus

Human Genome Sciences is one of several developers working on a new advance for lupus. This Wall Street Journal piece looks at the pipeline for lupus, which includes programs at Bristol-Myers Squibb, Genentech and Biogen Idec. There hasn't been a new therapy approved for lupus in 50 years, but these new drugs--which include Orencia and Rituxan--are being tested as treatments for the disease rather than just the symptoms.

- read the The Wall Street Journal article on lupus

Suggested Articles

MPM and Dana-Farber have formed a venture philanthropy alliance, raising a $100 million fund and $26 million in donations to support basic research.

IMV’s lead immunotherapy stopped ovarian cancer from getting worse in more than three-quarters of patients in a small phase 2 study.

The money will fund early-phase development of a CD47x4-1BB bispecific that Kahr plans to test with Roche’s checkpoint inhibitor Tecentriq.